← Leaderboards
Hariom Yadav
Wake Forest University Health Sciences
$5,459,448
Attributed
$7,011,710
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,011,710 · 8
By mechanism
U01$2,257,874 · 1
R56$1,595,996 · 2
R21$1,276,007 · 3
RF1$1,128,405 · 1
R01$753,428 · 1
Top collaborators
- Dalane W Kitzman3 shared
- Daniel B Kim-Shapiro2 shared
- Michal Mateusz Masternak1 shared
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- Victoria Weis$905,966
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposGut MicrobiotaMicrobialSourceMouse ModelBaseClinical ResearchAffectProductionMicrobiotaS DiseaseElderlyAgingMultidisciplinaryLinkDisease MarkerLeaky GutMediatingBacteriaImpaired CognitionCognitionInflammationBrainMicrobiome
Grant awards (14)
Microbial therapy improves gut permeability to reduce cognitive decline and Alzheimerâs disease$367,829
R01 · FY2025 · AG · contact PI
Repurposing of Metormin for Older Patients with HFpEF$738,245
U01 · FY2024 · AG
miRNAs in the gut-brain axis to predict the risk of cognitive decline in older adults$424,952
R21 · FY2024 · AG · contact PI
Microbial therapy improves gut permeability to reduce cognitive decline and Alzheimerâs disease$385,599
R01 · FY2024 · AG · contact PI
Identification of bacterial strains for development of an oral probiotic aimed at increasing nitric oxide bioavailability$223,916
R21 · FY2024 · DE
Repurposing of Metormin for Older Patients with HFpEF$739,149
U01 · FY2023 · AG
Identification of bacterial strains for development of an oral probiotic aimed at increasing nitric oxide bioavailability$197,783
R21 · FY2023 · DE
Repurposing of Metormin for Older Patients with HFpEF$780,480
U01 · FY2022 · AG
Microbial therapy improves gut permeability to reduce cognitive decline and Alzheimerâs disease$1,128,405
RF1 · FY2021 · AG · contact PI
Gut microbiota-based biomarkers of Alzheimer's disease and its modulation by a ketogenic diet$604,248
R56 · FY2021 · AG · contact PI
The role of gut microbiota in the efficacy of ketogenic diet to ameliorate Alzheimer's disease$429,356
R21 · FY2021 · AG · contact PI
Gut microbiota-based biomarkers of Alzheimer's disease and its modulation by a ketogenic diet$604,248
R56 · FY2020 · AG · contact PI
Metformin and Alzheimer's disease: Underlying Mechanisms that Ameliorate Progression$294,450
R56 · FY2020 · AG · contact PI
Metformin and Alzheimer's disease: Underlying Mechanisms that Ameliorate Progression$93,050
R56 · FY2020 · AG · contact PI